Literature DB >> 29929441

Imipridone ONC201: combination therapy in hematologic malignancies.

Ajai Chari1, Bart Barlogie1.   

Abstract

Entities:  

Keywords:  ONC201; imipridone; leukemia; lymphoma; multiple myeloma

Mesh：

Substances：

Year:  2018        PMID： 29929441      PMCID： PMC6224273          DOI： 10.1080/15384101.2018.1490861

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  5 in total

1.  First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.

Authors:  Mark N Stein; Joseph R Bertino; Howard L Kaufman; Tina Mayer; Rebecca Moss; Ann Silk; Nancy Chan; Jyoti Malhotra; Lorna Rodriguez; Joseph Aisner; Robert D Aiken; Bruce G Haffty; Robert S DiPaola; Tracie Saunders; Andrew Zloza; Sherri Damare; Yasmeen Beckett; Bangning Yu; Saltanat Najmi; Christian Gabel; Siobhan Dickerson; Ling Zheng; Wafik S El-Deiry; Joshua E Allen; Martin Stogniew; Wolfgang Oster; Janice M Mehnert
Journal:  Clin Cancer Res       Date:  2017-03-22       Impact factor: 12.531

2.  Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Authors:  Joshua E Allen; Gabriel Krigsfeld; Patrick A Mayes; Luv Patel; David T Dicker; Akshal S Patel; Nathan G Dolloff; Evangelos Messaris; Kimberly A Scata; Wenge Wang; Jun-Ying Zhou; Gen Sheng Wu; Wafik S El-Deiry
Journal:  Sci Transl Med       Date:  2013-02-06       Impact factor: 17.956

3.  Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.

Authors:  Varun V Prabhu; Mala K Talekar; Amriti R Lulla; C Leah B Kline; Lanlan Zhou; Junior Hall; A Pieter J Van den Heuvel; David T Dicker; Jawad Babar; Stephan A Grupp; Mathew J Garnett; Ultan McDermott; Cyril H Benes; Jeffrey J Pu; David F Claxton; Nadia Khan; Wolfgang Oster; Joshua E Allen; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2018-02-19       Impact factor: 4.534

Review 4.  Discovery and clinical introduction of first-in-class imipridone ONC201.

Authors:  Joshua E Allen; C Leah B Kline; Varun V Prabhu; Jessica Wagner; Jo Ishizawa; Neel Madhukar; Avital Lev; Marie Baumeister; Lanlan Zhou; Amriti Lulla; Martin Stogniew; Lee Schalop; Cyril Benes; Howard L Kaufman; Richard S Pottorf; B Rao Nallaganchu; Gary L Olson; Fahd Al-Mulla; Madeleine Duvic; Gen Sheng Wu; David T Dicker; Mala K Talekar; Bora Lim; Olivier Elemento; Wolfgang Oster; Joseph Bertino; Keith Flaherty; Michael L Wang; Gautam Borthakur; Michael Andreeff; Mark Stein; Wafik S El-Deiry
Journal:  Oncotarget       Date:  2016-11-08

5.  A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.

Authors:  Isabel Arrillaga-Romany; Andrew S Chi; Joshua E Allen; Wolfgang Oster; Patrick Y Wen; Tracy T Batchelor
Journal:  Oncotarget       Date:  2017-05-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.